Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.
Rasagiline Mesylate Tablets 1 mg Recalled by Ascend Laboratories, LLC Due to Presence of Foreign Substance- A complaint was received...
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact Ascend Laboratories, LLC directly.
Affected Products
Rasagiline Mesylate Tablets 1 mg; 30 tablets in HDPE bottle; Rx only; NDC 67877-260-30; Manufactured by Alkem Laboratories Ltd., India; Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054
Quantity: 12192 bottles
Why Was This Recalled?
Presence of Foreign Substance- A complaint was received of black spots/shiny metallic speck on the tablets.
Where Was This Sold?
This product was distributed to 19 states: CA, FL, GA, IL, KY, LA, MI, MN, MS, NJ, NY, NC, OH, PA, RI, TN, TX, WA, WI
About Ascend Laboratories, LLC
Ascend Laboratories, LLC has 26 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report